Диссертация (1155060), страница 20
Текст из файла (страница 20)
PLoS Med. – 2013.10(9):e1001510.115.Mocroft, A., Youle, M., Moore, A., et al. Reasons for modification anddiscontinuation of antiretrovirals: results from a single treatment centre //AIDS. -2001.–V.15(2).– 185-94.116.Montessori, V. Adverse effects of antiretroviral therapy for HIV infection / V.Montessori, N. Press, M. Harris et al // CMAJ. –2004.–V.170(2).– P.229-38.117.Nachega, J.B. Treatment simplification in HIV-infected adults as a strategy toprevent toxicity, improve adherence, quality of life and decrease healthcarecosts/ J.B. Nachega, M.J.
Mugavero, M. Zeier, M. et al / Patient PreferAdherence. – 2011.– V.5.–P.357-367.118.Nepal, B. Population mobility and spread of HIV across the Indo-Nepalborder. J Health Popul Nutr. – 2007. - 25(3):267–277.119.Norcross, M.A. Abacavir induces loading of novel self-peptides into HLAB*57: 01: an autoimmune model for HLA-associated drug hypersensitivity123/M.A. Norcross, S.
Luo, L. Lu, M.T. Boyne, M. Gomarteli, A.D. Rennels//AIDS. 2012 Jul 17;26(11):F21-9.120.O'Brien, M. E. Patterns and Correlates of Discontinuation of the InitialHAART Regimen in an Urban Outpatient Cohort / M.E. O'Brien, R.A. Clark,C.L. Besch// J Acquir Immune DeficSyndr.- 2003.- V.34. P.407-14.121.PalellaJr, F.J. Durability and predictors of success of highly activeantiretroviral therapy for ambulatory HIV-infected patients / F.J. PalellaJr, J.S.Chmiel, A.C. Moorman, // AIDS. –2002.–V.16(12).– P.1617-1626.122.Pierson, T., McArthur, J., Siliciano, R.F.
Reservoirs for HIV-1: Mechanismsfor viralpersistence in the presence of antiviral immune responses andantiretroviral therapy.Annu Rev Immunol18:665–708. -2000.123.Plewes, K., Lee, T., Kajeechewa, L., et al. Low seroprevalence of HIV andsyphilis in pregnant women in refugee camps on the Thai-Burma border. Int JSTD AIDS. 2008;19(12):833–837.124.Pokrovskiy, V. HIV epidemic in Russia and neighbouring countries. J IntAIDS Soc. 2014 Nov 2;17(4 Suppl 3):19502.125.Poudel, K.C., Jimba, M., Poudel-Tandukar, K., Wakai, S. Reaching hard-toreach migrants by letters: an HIV/AIDS awareness programme in Nepal.Health Place.
2007. - 3(1):173–178.126.Rachlis, B., Brouwer, K.C., Mills, E.J., Hayes, M., Kerr, T., Hogg, R.S.Migration and transmission of blood-borne infections among injection drugusers: understanding the epidemiologic bridge. Drug Alcohol Depend. – 2007.- 90(2–3):107–119.127.Rangel, M.G., Martinez-Donate, A.P., Hovell, M.F., et al. A two-way road:rates of HIV infection and behavioral risk factors among deported Mexicanlabor migrants. AIDS Behav. – 2012.
-16(6):1630–1640.128.Rebecca Pavlos and Elizabeth J Phillips Individualization of antiretroviraltherapy. Pharmgenomics Pers Med. 2012. - 5: 1–17.124129.Rosen, S., Vincent, J.R., MacLeod, W., Fox, M., Thea, D.M., Simon, J.L. Thecost of HIV/AIDS to businesses in southern Africa. AIDS. – 2004. 18(2):317–324.130.Rutta, E. Prevention of mother-to-child transmission of HIV in a refugee campsetting in Tanzania./ E. Rutta, R. Gongo, A. Mwansasu et al. // Glob PublicHealth.
– 2008. - 3(1): Р. 62–76.131.Sabin, C.A., Worm, S.W., Weber, R., et al. Use of nucleoside reversetranscriptase inhibitors and risk of myocardial infarction in HIV-infectedpatients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008. - 371(9622):1417.132.Schackman, B.R, Gebo, K.A, Walensky, R.P., et al The lifetime cost ofcurrent human immunodeficiency virus care in the United States// MedCare.
2006 V.44(11).– P.990-7.133.Sloan, C.E. Cost-Effectiveness of Preventing AIDS Complications (CEPAC)investigators. Newer drugs and earlier treatment: impact on lifetime cost ofcare for HIV-infected adults / C.E. Sloan, K. Champenois, P. Choisy et al //AIDS. – 2012.- V. 26(1). P.45-56.134.Smit, M. Could better tolerated HIV drug regimens improve patient outcome?/ M.
Smit, C. Smit, I. Cremin et al // AIDS. - 2012.- V26(15). – P.1953-1959.135.Sodora,D.L.,Silvestri,G.ImmuneactivationandAIDSpathogenesis.AIDS22(4):439–446. -2008.136.Sowell, R.L. HIV infection returning to Mexico with migrant workers: anexploratory study. /R.L. Sowell, C.S.
Holtz, G. Velasquez //J Assoc NursesAIDS Care. – 2008. - 19(4). - Р.267–282.137.Stover, J. Long-term costs and health impact of continued global fund supportfor antiretroviral therapy/ J. Stover, E.L. Korenromp, M. Blakley et al // PLoSOne.- 2011. V.6. – P.57-76.125138.Tanaka, Y. Knowledge, attitude, and practice (KAP) of HIV prevention andHIV infection risks among Congolese refugees in Tanzania / Y. Tanaka, O.Kunii, T. Hatano, S.
Wakai// Health Place. – 2008. - 14(3). - Р.434–452.139.Tansey, E. Southern Africa ports as spaces of HIV vulnerability: case studiesfrom South Africa and Namibia/ E. Tansey, N. Theyise, R. Borland, H.West//Int Marit Health. – 2010. - 62(4). P. 233–240.140.Tebas, P., Henry, K., Nease, R., Murphy, R., Phair, J., Powderly, W.G. Timingof antiretroviral therapy. Use of Markov modeling and decision analysis toevaluate the long-term implications of therapy. AIDS 2001. 15 (N5):591-599.141.The Stanford Guide to HIV/AIDS therapy., eds. M.A.Sande, D.N.Gilbert,R.C.Moeling (Hyde Park: Antimicrobal Therapy Inc.Press).
- 2000. - 133р.142.Thompson, M.A. Antiretroviral Treatment of Adult HIV Infection 2010Recommendations of the International AIDS Society USA Panel / M.A.Thompson, J.A. Aberg, P. Cahn et al // J.A.M.A. – 2010. – 304. – Р.321–333.143.Umenai, T., Narula, M., Onuki, D., Yamamoto, T., Igari, T. International HIVand AIDS prevention: Japan/United States collaboration.
J Acquir ImmuneDefic Syndr Hum Retrovirol. – 1997. -14(Suppl. 2):S58–S67.144.UNAIDS. Global Report on the AIDS Epidemic 2012. – Geneva : UNAIDS,2012.ресурс][Электронный–Режимдоступа:http://www.unaids.org/sites/default/files/media_asset/20121120_UNAIDS_Global_Report_2012_with_annexes_en_1.pdf(дата обращения:03.12.2016).145.United Nations Development Programme Asia-Pacific Regional Centre.Regional Dialogue on the Health Challenges for Asian Labour Migrants[Электронныйресурс].Bangkok:UNDP;2010.Режимдоступа:http://www.globalmigrationgroup.org/system/files/uploads/gmgtopics/health/Regional_Dialogue_on_the_Health_Challenges_for_Asian.pdf(дата обращения:17.12.2016).146.Vermund, S.H.
Millions of life-years saved with potent antiretroviral drugs inthe United States: a celebration, with challenges. /S.H. Vermund // J InfectDis. – 2006.– V. 194. –P.1-5.126147.Wainberg, M.A. Development of antiretroviral drug resistance / M.A.Wainberg, G.J.
Zaharatos, B.G. Brenner // N Engl J Med. – 2011 .–V 365. –P. 637-46.148.Walensky, R.P. The survival benefits of AIDS treatment in the United States./ R.P. Walensky, A.D. Paltiel, E. Losina et al. // J Infect Dis.– 2006.–V.194(1). – P. 11-19.149.Walley, T., A. Haycox, A. Boland. Pharmacoeconomics. – Elsevier Science,2004. – с. 122-123.150.WHO: Antiretroviral therapy for HIV infection in adults and adolescents,Guidenlines [Электронный ресурс]. March 2010. Режим доступа:http://www.who.int/topics/hiv_aids/en/index.html(датаобращения09.01.2017).151.Willig, J.H.
Increased regimen durability in the era of once-daily fixed-dosecombination antiretroviral therapy / J.H. Willig, S. Abroms, A.O. Westfall etal // AIDS. – 2008.-V.22(15). – P.1951-1965.152.Woldemedhin, B. The Reason for Regimen Change Among HIV/AIDSPatients Initiated on First Line Highly Active Antiretroviral Therapy inSouthern Ethiopia / B. Woldemedhin, N.T. Wabe // N Am J Med Sci.– 2012.–V.4(1).– P.19-23.153.Wolff, M. Clinical and virologic outcomes after changes in first antiretroviralregimen at 7 sites in the Caribbean, Central and South America Network(CCASAnet) / M.
Wolff, B.E. Shepherd, C.P. Cortés, P. Rebeiro, C. Cesar, S.Wagner Cardoso et als // J Acquir Immune Defic Syndr. – 2016. -71 (1). –Р.102–110.154.Yakun'kina TA Comparative pharmacoeconomic analysis of the cost ofantiretroviral therapy for the treatment of patients with HIV infection: dip ...060108 - Pharmacy / T.A.Yakunkina//. -M., 2015.-80s.127155.Zhou, F. Expenditures for the care of HIV-infected patients in rural areas inChina's antiretroviral therapy programs / F. Zhou, G.F. Kominski, H.Z.
Qian// BMC Med. - 2011.- V. 17. – P.179-190.128ПРИЛОЖЕНИЕ 1.Карта пациентаНомер карты пациента |__|__|__|__|__|Дата рождения |__|Клиническая стадия СПИД (ВОЗ) |__| (1 - 4)Год рождения|__|__|__|__| Пол |__| (1-М,2-Ж) Дата иммунного блота |__|__|__|__|Социальный статус|__| (1-да, 2-нет, 3-НД)Путь инфицирования: парентерально наркотики |__| гомо/гетеросексуальный путьпередачи |__| не установлено |__|другие__________________________Сопутствующиезаболевания|__|(1-да,2-нет)какие_____________________________Длительность заболевания____________ Уровень CD4 нач_______УровеньСD4№2_____ Аллергические реакции______Причина замены схемы терапии:клиническая неэффективность |__|вирусологическая неэффективность |__| наличие побочных эффектов |__|Побочные эффекты: _____________________________________________Общий анализ крови|__|гемоглобин_______лейкоциты ________тромбоциты________ анализ мочи |__| _____________ЦНС____________________________________________________________Гиперчувствительность________________________Другое_______________________Причина замены терапии_____________________________________Тест HLA-B*5701___________________________Дата отмены_____________________Симптомы ABC-HsR_________________________Консультации специалистов__________Сопутствующая терапия____________________129Анализ назначаемой АРТСтартовая терапияНИОТЗиаген (ABC)Диданозин (ddI)Зидовудин (ZDV)Ламивудин (3ТС)Ставудин (d4T)Тенофовир (TDF)Фосфазид (Ф-АЗТ)ННИОТНевирапин (NVP)Рилпивирин (RPV)Этравирин (ETR)Эфавиренз (EFV)ИПФосфампренавир (FPV)Атазановир (ATZ)Дарунавир (DRV)Нелфинавир (NFV)Ритонавир (RTV)Саквинавир (SQV)КомбиКивекса (АВС/3TC)Комбивир (3TC/ZDV)Калетра (RTV/ЛПВ)ДругиеРалтегравир (RAL)Энфувиртид (Т-20)Терапия второгоряда130ПРИЛОЖЕНИЕ 2.№ Лекарственнып/е препаратып(МНН)ТорговыеДозировка,Количествонаименовани лекарственнаяяформаНуклеозидные ингибиторы обратной транскриптазы (НИОТ)1АбакавирАбакавир-АВСТабл.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
